Hepatocellular carcinoma (HCC) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-A1AT-DEFICIENCY-HCC-LUNG-PREVENTION-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-HCC`
Sources	`SRC-AASLD-HCC-2023` `SRC-NCCN-BCELL-2025` `SRC-NCCN-NSCLC-2025`

Notes

STUB — v0.3 chronic-condition prevention pilot (A1AT / HCC + lung). Two-Co-Lead signoff queued. Multi-organ surveillance pathway in one Indication; future enhancement could split into hepatic-anchored vs pulmonary-anchored Indications, but current §15.2 C4 requirements are met by the 2-track shape (this active surveillance + observation alternative).

Used By

Indication

IND-A1AT-DEFICIENCY-HCC-LUNG-PREVENTION-OBSERVATION - IND-A1AT-DEFICIENCY-HCC-LUNG-PREVENTION-OBSERVATION

Red flag

RF-A1AT-DEFICIENCY-HCC-LUNG-PREVENTION - Alpha-1 antitrypsin (A1AT) deficiency, particularly homozygous PiZZ genotype (severe defi...